Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
SAMe 对 UBC9 的作用以及肝癌和酒精性肝损伤中的求和作用
基本信息
- 批准号:8320778
- 负责人:
- 金额:$ 5.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-30 至 2013-09-29
- 项目状态:已结题
- 来源:
- 关键词:APEX1 geneAcuteAddressAffectAfricaAge-MonthsAlcoholic Liver CirrhosisAlcoholic Liver DiseasesAlcoholsAnabolismAntioxidantsApoptosisApoptoticAreaAsiaAttentionBiologicalBreast Cancer CellCancer EtiologyCatalytic DomainCell LineCell TransplantsCellsCellular Stress ResponseCessation of lifeChemicalsChronicCirrhosisCountryDNA DamageDNA RepairDevelopmentDown-RegulationEnzymesEthanolExhibitsFamily memberFatty LiverGene ProteinsGenesGenome StabilityGenotoxic StressGlutathioneGrowthHalf-LifeHealthHepaticHepatitis CHepatocarcinogenesisHepatocyteHumanIncidenceInflammationInjuryInjury to LiverIsoenzymesKnock-outKnockout MiceLeadLigationLipid PeroxidationLiverLung AdenocarcinomaMCF7 cellMalignant NeoplasmsMalignant neoplasm of liverMammalian CellMammalsMediatingMessenger RNAMethionineMethionine Metabolism PathwayModelingMusMutateMutationNF-kappa BNuclearNude MiceOvarian CarcinomaOxidative StressPathway interactionsPatientsPhosphoric Monoester HydrolasesPhosphorylationPhosphorylation SitePlayPolyaminesPost-Translational Protein ProcessingPrecancerous ConditionsPrevalencePrimary carcinoma of the liver cellsProcessProteinsRNA InterferenceReportingRodentRoleS-AdenosylmethionineSignal PathwaySiteSteatohepatitisSubstrate SpecificitySystemTestingTranslational RepressionUbiquitinUbiquitin Like ProteinsUbiquitin-Conjugating EnzymesUp-RegulationWild Type Mousealcohol responsecancer cellcell growthcholine deficient dietchronic liver diseasefallsfeedinghepatoma cellimprovedin vivoinhibitor/antagonistinsightknock-downmelanomamethionine adenosyltransferasenoveloverexpressionpolypeptidepreventprotein expressionprotein protein interactionpublic health relevanceresponsetherapy developmenttumor progressiontumorigenesisvector
项目摘要
DESCRIPTION (provided by applicant): Posttranslational modifications mediated by ubiquitin-like proteins regulate a variety of cellular pathways. Although small ubiquitin-like modifier (SUMO) is a new member of this family, it has attracted a great deal of attention recently because of its novel and distinct functions. The sumoylation cycle is a multistep process, involving maturation, activation, conjugation and ligation; it is catalyzed by multiple enzymes, including E1, E2 and E3 enzymes. Ubiquitin-conjugating enzyme 9 (UBC9) is the sole E2 conjugating enzyme and is the best characterized enzyme in the sumoylation cycle. UBC9 transfers the activated SUMO to the target protein and is believed to play an important role in regulating the substrate specificity and enhancing the efficiency of sumoylation in vivo. Genotoxic stress induces sumoylation of a broad number of proteins involved in nuclear function as well as proteins involved in important signaling pathways, such as the nuclear factor kappa B (NF- :B). UBC9 and SUMO are highly expressed in human premalignant conditions in response to low-grade, long- term genotoxic stress, implying that upregulation of sumoylation may be an adaptive process to genotoxic stress. Furthermore, UBC9 is overexpressed in several malignancies, such as lung adenocarcinoma, ovarian carcinoma, and melanoma. Antagonizing UBC9 function in MCF-7 breast cancer cells transplanted in nude mice inhibited cell growth and increased apoptosis via Bcl-2 dependent mechanisms. Inactivating mutations of UBC9's SUMO conjugating activity enhances sensitivity to DNA damaging agents. UBC9 may be fundamental for tumorigenesis and tumor progression by preventing activation of apoptotic pathways and by minimizing the acute cellular stress response associated with the accumulating DNA damage of tumor progression. Whether UBC9 is deregulated in hepatocellular carcinoma (HCC) is unknown. How UBC9 protein stability is regulated post-translationally is also unknown. Finally, whether UBC9 expression is altered in response to alcohol is also unknown. S-adenosylmethionine (SAMe) is the principle biological methyl donor that is made in all mammalian cells as the first product of methionine metabolism, catalyzed by methionine adenosylmethionine (MAT). Besides being a methyl donor, accumulating evidence show SAMe regulates many critical cellular pathways that control growth and apoptosis. In mammals two MAT genes, MAT1A and MAT2A, encode for two catalytic subunits of MAT, 11 and 12, respectively. Patients with chronic liver disease including alcohol have impaired hepatic SAMe biosynthesis due to decreased MAT1A mRNA levels and post-translational inhibition of the MAT1A-encoded isoenzymes. Chronic hepatic SAMe deficiency occurs in MAT1A knockout (KO) mice, which exhibit increased propensity to choline-deficient diet induced fatty liver, higher level of lipid peroxidation, spontaneous development of steatohepatitis and HCC. We have recently shown that there is increased genotoxic stress in this model as early as at one month of age. Consistently, we found UBC9 expression is increased in the MAT1A KO livers and importantly administration of SAMe lowered UBC9 expression at the protein level. Treatment of HepG2 and HuH-7 cells, two human hepatoma cell lines, with SAMe also lowered the UBC9 protein level. This is a surprise finding as we reported recently that SAMe inhibits proteosomal activity. Since alcohol feeding lowers hepatic SAMe level, we also examined whether UBC9 expression is altered in this model and found that like the MAT1A KO livers, hepatic UBC9 protein level is increased in response to alcohol feeding. In this proposal we are testing several novel hypotheses, 1) UBC9 protein half-life is affected by phosphorylation so that phosphorylation at critical site(s) protects against degradation, 2) SAMe and its metabolite methylthioadenosine (MTA) can lower the UBC9 protein half-life by lowering its phosphorylation at these critical sites, 3) SAMe and MTA, known to be pro-apoptotic in liver cancer cells, cause apoptosis by lowering UBC9 expression, 4) UBC9 expression and hence sumoylation are increased during the development of alcoholic liver injury and they may contribute to many of the abnormalities seen. Three aims are proposed in this application to test these hypotheses and elucidate how SAMe affects signaling pathways that are important in hepatocarcinogenesis and development of alcoholic liver injury.
描述(由申请人提供):由泛素样蛋白介导的翻译后修饰调节多种细胞途径。小泛素样修饰物(SUMO)是该家族的新成员,但由于其新颖独特的功能,近年来引起了人们的广泛关注。类小泛素化循环是一个多步骤的过程,涉及成熟、活化、缀合和连接;它由多种酶催化,包括E1、E2和E3酶。泛素结合酶9(UBC 9)是唯一的E2结合酶,也是sumoylation循环中最具特征的酶。UBC 9将激活的SUMO转移到靶蛋白,并被认为在调节底物特异性和提高体内SUMO化效率方面发挥重要作用。遗传毒性应激诱导参与核功能的大量蛋白质以及参与重要信号传导途径的蛋白质(如核因子κ B(NF-:B))的类小泛素化。UBC 9和SUMO在人类癌前病变中响应于低等级、长期遗传毒性应激而高度表达,这意味着SUMO化的上调可能是对遗传毒性应激的适应性过程。此外,UBC 9在几种恶性肿瘤中过表达,如肺腺癌、卵巢癌和黑色素瘤。在裸鼠移植的MCF-7乳腺癌细胞中拮抗UBC 9功能可抑制细胞生长,并通过Bcl-2依赖机制增加凋亡。UBC 9的SUMO缀合活性的失活突变增强了对DNA损伤剂的敏感性。UBC 9可能是肿瘤发生和肿瘤进展的基础,通过防止细胞凋亡途径的激活和最小化与肿瘤进展的累积DNA损伤相关的急性细胞应激反应。UBC 9在肝细胞癌(HCC)中是否失调尚不清楚。UBC 9蛋白的稳定性如何在免疫后调节也是未知的。最后,UBC 9的表达是否会因酒精而改变也是未知的。S-腺苷甲硫氨酸(SAMe)是主要的生物甲基供体,在所有哺乳动物细胞中作为甲硫氨酸代谢的第一产物,由甲硫氨酸腺苷甲硫氨酸(MAT)催化。除了作为甲基供体,越来越多的证据表明SAMe调节许多控制生长和凋亡的关键细胞通路。在哺乳动物中,两个MAT基因MAT 1A和MAT 2A分别编码MAT的两个催化亚基11和12。由于MAT 1A mRNA水平降低和MAT 1A编码同工酶的翻译后抑制,慢性肝病(包括酒精)患者的肝脏SAMe生物合成受损。MAT 1A基因敲除(KO)小鼠出现慢性肝脏SAMe缺乏症,表现出缺乏胆碱饮食诱导的脂肪肝倾向增加、脂质过氧化水平升高、自发发生脂肪性肝炎和肝癌。我们最近发现,早在一个月大的时候,这个模型中的遗传毒性应激就增加了。一致地,我们发现UBC 9表达在MAT 1A KO肝脏中增加,并且重要的是,SAMe的施用在蛋白质水平上降低了UBC 9表达。用SAMe处理HepG 2和HuH-7细胞(两种人肝癌细胞系)也降低了UBC 9蛋白水平。这是一个令人惊讶的发现,因为我们最近报道了SAMe抑制蛋白酶体活性。由于酒精喂养降低了肝脏SAMe水平,我们还检查了UBC 9表达在该模型中是否改变,并发现与MAT 1A KO肝脏一样,肝脏UBC 9蛋白水平响应于酒精喂养而增加。在该提案中,我们正在测试几种新的假设,1)UBC 9蛋白半衰期受到磷酸化的影响,使得在关键位点的磷酸化防止降解,2)SAMe及其代谢物甲硫腺苷(MTA)可以通过降低UBC 9蛋白在这些关键位点的磷酸化来降低其半衰期,3)已知在肝癌细胞中促凋亡的SAMe和MTA,通过降低UBC 9表达引起细胞凋亡,4)在酒精性肝损伤的发展过程中,UBC 9表达和sumoylation增加,它们可能导致许多观察到的异常。在本申请中提出了三个目标来测试这些假设,并阐明SAMe如何影响在肝癌发生和酒精性肝损伤发展中重要的信号通路。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.
- DOI:10.1007/s13402-011-0067-z
- 发表时间:2012-06
- 期刊:
- 影响因子:0
- 作者:Frau M;Simile MM;Tomasi ML;Demartis MI;Daino L;Seddaiu MA;Brozzetti S;Feo CF;Massarelli G;Solinas G;Feo F;Lee JS;Pascale RM
- 通讯作者:Pascale RM
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.
- DOI:10.18632/oncotarget.26838
- 发表时间:2019-04-19
- 期刊:
- 影响因子:0
- 作者:Simile, Maria M;Peitta, Graziella;Pascale, Rosa M
- 通讯作者:Pascale, Rosa M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria Lauda Tomasi其他文献
S-Adenosylmethionine Inhibits Plasminogen-Activating Inhibitor-1 and Protects Male Mice from FOLFOX-Induced Liver Injury
S-腺苷甲硫氨酸抑制纤溶酶原激活物抑制剂-1 并保护雄性小鼠免受 FOLFOX 诱导的肝损伤
- DOI:
10.1016/j.jcmgh.2025.101513 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:7.400
- 作者:
Alexandra Gangi;Tony W.H. Li;Youngyi Lim;Swati Chandla;Andrea Floris;Arash Khangholi;Maria Lauda Tomasi;Shelly C. Lu - 通讯作者:
Shelly C. Lu
Sa1688 Polyamine and Methionine Adenosyltransferase 2A Crosstalk in Human Colon Cancer
- DOI:
10.1016/s0016-5085(13)61001-x - 发表时间:
2013-05-01 - 期刊:
- 影响因子:
- 作者:
Maria Lauda Tomasi;Minjung Ryoo;Anna Skay;Ivan Tomasi;Pasquale Giordano;Jose M. Mato;Shelly C. Lu - 通讯作者:
Shelly C. Lu
The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis
叉头框 M1-甲硫氨酸腺苷转移酶 2A/2B 轴在肝脏炎症和纤维化中的作用
- DOI:
10.1038/s41467-024-52527-8 - 发表时间:
2024-09-27 - 期刊:
- 影响因子:15.700
- 作者:
Bing Yang;Liqing Lu;Ting Xiong;Wei Fan;Jiaohong Wang;Lucía Barbier-Torres;Jyoti Chhimwal;Sonal Sinha;Takashi Tsuchiya;Nirmala Mavila;Maria Lauda Tomasi;DuoYao Cao;Jing Zhang;Hui Peng;José M. Mato;Ting Liu;Xi Yang;Vladimir V. Kalinichenko;Komal Ramani;Jenny Han;Ekihiro Seki;Heping Yang;Shelly C. Lu - 通讯作者:
Shelly C. Lu
EP1205: S-ADENOSYLMETHIONINE PROTECTS AGAINST CHEMOTHERAPY INDUCED LIVER INJURY
- DOI:
10.1016/s0016-5085(22)63766-1 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Alexandra Gangi;Tony W. Li;Andrea Floris;Jiaohong Wang;Maria Lauda Tomasi;Shelly C. Lu - 通讯作者:
Shelly C. Lu
Tu2026 - StarD10 as a Novel Diagnostic Marker in Colon Cancer
- DOI:
10.1016/s0016-5085(17)35377-5 - 发表时间:
2017-04-01 - 期刊:
- 影响因子:
- 作者:
Andrea Floris;ivan tomasi;Maria Lauda Tomasi - 通讯作者:
Maria Lauda Tomasi
Maria Lauda Tomasi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria Lauda Tomasi', 18)}}的其他基金
Role of StAR-related lipid transfer protein 10 in alcohol-induced breast cancer progression
StAR相关脂质转移蛋白10在酒精诱导的乳腺癌进展中的作用
- 批准号:
10734533 - 财政年份:2023
- 资助金额:
$ 5.42万 - 项目类别:
Role of phospho UBC9 in alcohol-associated liver disease
磷酸化 UBC9 在酒精相关性肝病中的作用
- 批准号:
10698107 - 财政年份:2022
- 资助金额:
$ 5.42万 - 项目类别:
A novel biological crosstalk between sumoylation and mitochondria dysfuntion in alcoholic liver disease
酒精性肝病中苏酰化和线粒体功能障碍之间的新型生物串扰
- 批准号:
10006497 - 财政年份:2019
- 资助金额:
$ 5.42万 - 项目类别:
Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
SAMe 对 UBC9 的作用以及肝癌和酒精性肝损伤中的求和作用
- 批准号:
8147672 - 财政年份:2010
- 资助金额:
$ 5.42万 - 项目类别:
ROLE OF S-ADENOSYLMETHIONINE ON UBC9 AND SUMOYLATION IN LIVER CANCER AND ALCOHOLI
S-腺苷甲硫氨酸对 UBC9 的作用以及肝癌和酒精中的苏酰化
- 批准号:
8061618 - 财政年份:2010
- 资助金额:
$ 5.42万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 5.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 5.42万 - 项目类别:
Operating Grants














{{item.name}}会员




